All the latest news on the marijuana space delivered directly to your inbox.
TheSeedInvestor
Biosynthesis: Unlocking the Medical Potential of Cannabis
View the infographic on how Biosynthesis could unlock the full medical potential of Cannabis, unlocking massive market potential. 

 
13x13x1 READ MORE
Read the Investors Guide To Newly Emerging Marijuana Markets 
LEARN MORE
600x300
The Therapeutic Potential of Pharmacologically Active Cannabinoids

InMed Pharmaceuticals, Inc. (CSE: IN) (OTC: IMLFF) has initiated a scientific paradigm shift in discovering potential breakthrough cannabinoid-based therapies that advances far beyond basic cannabinoid production and the over-the-counter sales of oils and elixirs.

13x13x1 READ MORE
600x300
ABcann Enters into Agreement to Acquire Leading Medical Cannabis Clinic

ABcann Global Corporation (TSXV:ABCN OTC: ABCCF) is pleased to announce that it has entered into a binding letter of intent dated December 11, 2017 to acquire all of the outstanding securities of Harvest Medicine Inc..

13x13x1 READ MORE
600x300
GW Pharma Closes $317.4 Million Equity Offering

GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $317.4 Million and Full Exercise of Underwriter’s Option to Purchase Additional ADSs

13x13x1 READ MORE
600x300
Aurora Cannabis Boosts Radient Technologies Stake to 17.2%

Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Radient Technologies Inc. (TSX-V: RTI) today announced that Aurora has completed its previously announced $12 million strategic investment in Radient.

13x13x1 READ MORE
600x300
Hydropothecary announces expansion plans to increase production capacity to 108,000 kilograms per year of dried cannabis

Expansion announcement set to make Hydropothecary one of the top cannabis producers in the country

13x13x1 READ MORE
Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 
 
32x32x1   32x32x2   32x32x3
TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260
info@theseedinvestor.com
 
©2018, All Rights Reserved  |  Unsubscribe   |   View this in Browser

To keep receiving emails from us, please add us to your address book.